Abstract: The study of 177Lu labeled radiopharmaceuticals for cancer therapy is fast emerging as an important part of nuclear medicine. Multidentate aminomethylenephosphonic acids could form well-characterized stable complexes with different β- emitting radionuclides and have already proven to be very effective for palliation of bone pain. 177Lu-EDTMP and 177Lu-DOTMP are possible to be effective radiopharmaceuticals for pain palliation due to bone cancer. At present, the labeling methods for 177Lu-EDTMP and 177Lu-DOTMP are established. The biodistributiion of 177Lu-EDTMP and 177Lu-DOTMP in normal mice is carried out as well.